Stockscreener 앱 받기
2.90
2.68%
-0.08
시간 외 거래:
2.86
-0.04
-1.38%
전일 마감가:
$2.98
열려 있는:
$2.96
하루 거래량:
777.10K
Relative Volume:
0.58
시가총액:
$184.31M
수익:
$149.50M
순이익/손실:
$-74.62M
주가수익비율:
-2.4499
EPS:
-1.1837
순현금흐름:
$-82.95M
1주 성능:
-7.05%
1개월 성능:
+67.63%
6개월 성능:
+79.01%
1년 성능:
+33.03%
1일 변동 폭
$2.81
$2.975
1주일 범위
$2.81
$3.25
52주 변동 폭
$0.9897
$3.54
Macrogenics Inc Stock (MGNX) Company Profile
명칭
Macrogenics Inc
전화
301-251-5172
주소
9704 MEDICAL CENTER DRIVE, Rockville, MD
Compare MGNX vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MGNX
Macrogenics Inc
|
2.90 | 189.40M | 149.50M | -74.62M | -82.95M | -1.1837 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.05 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.45 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.50 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.72 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
Macrogenics Inc Stock (MGNX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-09-17 | 재개 | Barclays | Overweight |
| 2024-11-07 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2024-08-01 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2024-07-31 | 다운그레이드 | B. Riley Securities | Buy → Neutral |
| 2024-07-31 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2024-05-10 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2024-05-10 | 다운그레이드 | Stifel | Buy → Hold |
| 2024-05-10 | 다운그레이드 | TD Cowen | Buy → Hold |
| 2024-04-26 | 개시 | B. Riley Securities | Buy |
| 2024-04-09 | 업그레이드 | TD Cowen | Hold → Buy |
| 2024-03-04 | 재확인 | BTIG Research | Buy |
| 2024-02-14 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2023-12-20 | 업그레이드 | Citigroup | Neutral → Buy |
| 2023-11-07 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2023-03-17 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2022-11-22 | 다운그레이드 | Cowen | Outperform → Market Perform |
| 2022-11-14 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2022-07-18 | 다운그레이드 | SMBC Nikko | Outperform → Neutral |
| 2022-07-11 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2022-05-04 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2022-02-28 | 업그레이드 | Citigroup | Neutral → Buy |
| 2022-02-11 | 개시 | BMO Capital Markets | Outperform |
| 2022-02-04 | 개시 | SMBC Nikko | Outperform |
| 2021-11-17 | 재개 | Guggenheim | Buy |
| 2021-10-19 | 개시 | JMP Securities | Mkt Outperform |
| 2021-10-15 | 재개 | BTIG Research | Buy |
| 2021-04-26 | 재개 | Credit Suisse | Outperform |
| 2021-03-12 | 업그레이드 | Barclays | Underweight → Overweight |
| 2020-12-22 | 재개 | H.C. Wainwright | Buy |
| 2020-08-03 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-06-01 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2020-05-26 | 재확인 | H.C. Wainwright | Buy |
| 2020-03-04 | 개시 | Barclays | Underweight |
| 2019-12-19 | 개시 | Cantor Fitzgerald | Overweight |
| 2019-12-18 | 개시 | Cantor Fitzgerald | Overweight |
| 2019-11-21 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2019-11-20 | 재개 | Guggenheim | Neutral |
| 2019-05-03 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2019-04-12 | 개시 | Guggenheim | Neutral |
| 2019-02-07 | 업그레이드 | Citigroup | Sell → Buy |
| 2019-02-07 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2019-02-06 | 업그레이드 | Raymond James | Underperform → Mkt Perform |
| 2019-02-04 | 다운그레이드 | Citigroup | Neutral → Sell |
| 2018-12-10 | 다운그레이드 | Raymond James | Outperform → Underperform |
| 2018-09-10 | 재개 | BTIG Research | Buy |
| 2018-05-31 | 개시 | Evercore ISI | Outperform |
| 2018-03-05 | 개시 | H.C. Wainwright | Buy |
| 2017-03-31 | 개시 | Raymond James | Outperform |
모두보기
Macrogenics Inc 주식(MGNX)의 최신 뉴스
Sentiment Review: Will MacroGenics Inc outperform the market in YEAR2026 Big Picture & Fast Gain Stock Tips - baoquankhu1.vn
Why is MacroGenics stock sinking Tuesday? - MSN
Bull Run: Is MacroGenics Inc attractive for institutional investorsWeekly Stock Analysis & Verified Momentum Watchlists - baoquankhu1.vn
MacroGenics Inc earnings missed by $0.03, revenue topped estimates - Investing.com Nigeria
MacroGenics (NASDAQ:MGNX) Upgraded to "Hold" at Wall Street Zen - MarketBeat
Who's Buying or Selling Macrogenics Inc (HAM:M55) Stock Today? - GuruFocus
Macrogenics Inc (HAM:M55) DCF Valuation - GuruFocus
MacroGenics at Barclays Conference: Strategic Therapeutic Focus By Investing.com - Investing.com Canada
MGNX: Multiple clinical milestones and strategic updates expected in 2026, backed by strong partnerships - TradingView
MacroGenics (NASDAQ:MGNX) Price Target Raised to $4.00 at Barclays - Defense World
MacroGenics (MGNX) Loss Of US$74.6 Million Tests Bullish Loss‑Narrowing Narrative - Sahm
Stifel reiterates MacroGenics stock rating with $4 price target By Investing.com - Investing.com Canada
Stifel reiterates MacroGenics stock rating with $4 price target - Investing.com Australia
MacroGenics at Leerink Global Healthcare Conference: Strategic Pipeline Focus By Investing.com - Investing.com Canada
Analysts Offer Insights on Healthcare Companies: MacroGenics (MGNX) and Cartesian Therapeutics (RNAC) - The Globe and Mail
MGNX Closes Up 45% On Wall Street Optimism For Experimental Cancer Therapies - Asianet Newsable
MGNX: Focused execution and pipeline progress set up major clinical milestones for mid-2026 - TradingView
Barclays Forecasts Strong Price Appreciation for MacroGenics (NASDAQ:MGNX) Stock - MarketBeat
MacroGenics (NASDAQ:MGNX) Announces Quarterly Earnings Results, Beats Estimates By $0.20 EPS - MarketBeat
Barclays Raises Price Target for Macrogenics (MGNX) to $4.00, Ma - GuruFocus
MacroGenics, Inc. 2025 Annual Report: Innovative Antibody-Based Cancer Therapeutics, Pipeline, and Risk Factors Overview - Minichart
MacroGenics Q4 2025 Earnings: Loss Below Estimates, Revenue Beats ForecastNews and StatisticsIndexBox - IndexBox - Market Intelligence Platform
MacroGenics (MGNX) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance
MacroGenics Reports 2025 Financial Results and Highlights Upcoming Planned Data Disclosures - Bitget
MacroGenics: Fourth Quarter Earnings Overview - Bitget
MacroGenics: Q4 Earnings Snapshot - marketscreener.com
MacroGenics : Corporate Overview March 2026 - marketscreener.com
MacroGenics (NASDAQ: MGNX) details 2025 results, cash runway and key 2026 data - Stock Titan
MacroGenics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Cancer biotech MacroGenics lines up 2026 trial data, funds into 2027 - Stock Titan
Chipmakers Recap: Can MacroGenics Inc expand its profit margins2026 Macro Moves & Low Risk Growth Stock Ideas - baoquankhu1.vn
Aug Breakouts: Can MacroGenics Inc disrupt its industryPortfolio Value Report & Long-Term Safe Investment Ideas - baoquankhu1.vn
MacroGenics Q1 2025 Earnings Preview - MSN
Risk Off: Will MacroGenics Inc. stock deliver consistent dividends2025 Growth vs Value & Detailed Earnings Play Strategies - Naître et grandir
Aug Retail: Will MacroGenics Inc outperform the market in YEARJuly 2025 Macro Moves & Long-Term Growth Plans - baoquankhu1.vn
Trade Recap: Can MacroGenics Inc expand its profit marginsWeekly Volume Report & Long-Term Growth Stock Strategies - baoquankhu1.vn
MacroGenics, Inc. (NASDAQ:MGNX) Given Average Rating of "Hold" by Analysts - MarketBeat
MGNX SEC FilingsMacrogenics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
MGNX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
MacroGenics at TD Cowen Conference: Strategic Imperatives in Focus - Investing.com
MacroGenics (MGNX) director Jay Siegel to step down after 2026 meeting - Stock Titan
MacroGenics, Inc. Announces Jay Siegel Not Stands for Re-Election as Class I Director, Effective February 25, 2026 - marketscreener.com
Whats the profit margin of MacroGenics IncEarnings Risk Report & Real-Time Volume Trigger Notifications - baoquankhu1.vn
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates C - GuruFocus
MacroGenics to Participate in Upcoming Investor Conferences - The Manila Times
Cancer drug developer MacroGenics lines up March investor talks - Stock Titan
FDA Partially Pauses Cancer Drug Trial After Patient Death - National Today
MacroGenics (MGNX) Reports Q1 Loss, Lags Revenue Estimates - MSN
MacroGenics stock falls after FDA places partial clinical hold - Investing.com South Africa
MacroGenics stock falls after FDA places partial clinical hold By Investing.com - Investing.com Australia
MacroGenics (MGNX) Faces FDA Setback with Partial Hold on Lorige - GuruFocus
Macrogenics Inc (MGNX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.20%
0.06%
자본화:
|
볼륨(24시간):